Those reports suggested that type I IFN might modulate the tumor microenvironment of melanoma, leading to enhanced therapeutic effects from appropriate anti-melanoma drugs, such as anti-PD1 Abs, although the precise mechanisms remain unknown. Here, PDCD1 is linked to neoplasm.